In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb−drug interactions in the management of COVID-19
Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of Ashwagandha and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction wit...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_eb85b8a9f70a4b0088ee7a96b3ce8891 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Siva Swapna Kasarla |e author |
700 | 1 | 0 | |a Siva Swapna Kasarla |e author |
700 | 1 | 0 | |a Swapnil P. Borse |e author |
700 | 1 | 0 | |a Yashwant Kumar |e author |
700 | 1 | 0 | |a Neha Sharma |e author |
700 | 1 | 0 | |a Neha Sharma |e author |
700 | 1 | 0 | |a Madhu Dikshit |e author |
700 | 1 | 0 | |a Madhu Dikshit |e author |
245 | 0 | 0 | |a In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb−drug interactions in the management of COVID-19 |
260 | |b Frontiers Media S.A., |c 2022-10-01T00:00:00Z. | ||
500 | |a 1663-9812 | ||
500 | |a 10.3389/fphar.2022.973768 | ||
520 | |a Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of Ashwagandha and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction with remdesivir, a drug used for COVID-19 management during the second wave. The study also implies possible herb−drug interactions as ashwagandha and AYUSH-64 are being used for managing various pathological conditions. Aqueous extracts of ashwagandha and AYUSH-64 were characterized using LC-MS/MS. A total of 11 and 24 phytoconstituents were identified putatively from ashwagandha and AYUSH-64 extracts, respectively. In addition, in silico studies revealed good ADME properties of most of the phytoconstituents of these herbal drugs and suggested that some of these might possess CYP-450 inhibitory activity. In vitro CYP-450 studies with human liver microsomes showed moderate inhibition of CYP3A4, 2C8, and 2D6 by remdesivir, while ashwagandha had no inhibitory effect alone or in combination with remdesivir. AYUSH-64 also exhibited a similar trend; however, a moderate inhibitory effect on CYP2C8 was noticed. Thus, ashwagandha seems to be safe to co-administer with the substrates of CYP3A4, CYP2C8, and CYP2D6. However, caution is warranted in prescribing AYUSH-64 along with CYP2C8 substrate drugs. Furthermore, preclinical and clinical PK studies would be helpful for their effective and safer use in the management of various ailments along with other drugs. | ||
546 | |a EN | ||
690 | |a Withania somnifera | ||
690 | |a Ayurveda | ||
690 | |a remdesivir | ||
690 | |a integrative medicine | ||
690 | |a Rasayana | ||
690 | |a LC-MS/MS | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Pharmacology, Vol 13 (2022) | |
787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2022.973768/full | |
787 | 0 | |n https://doaj.org/toc/1663-9812 | |
856 | 4 | 1 | |u https://doaj.org/article/eb85b8a9f70a4b0088ee7a96b3ce8891 |z Connect to this object online. |